BioSig
Technologies Inc. Appoints Tony Zook to the Board of Directors
Former
President and CEO of the North American division of AstraZeneca Plc
to join as Independent Director
Westport, CT -- July 1, 2020 -- InvestorsHub NewsWire -- BioSig
Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a
medical technology company commercializing a proprietary biomedical
signal processing platform designed to improve signal fidelity and
uncover the full range of ECG and intra-cardiac signals, today
appointed Mr. Anthony (‘Tony’) Zook to its Board of Directors.
Mr. Zook brings to the Company a wealth of commercialization
experience in the life science industry gained primarily through
his career at AstraZeneca Plc [LON:AZN]. Mr. Zook held several
executive positions at AstraZeneca, including Executive Vice
President of Global Commercial Operations from 2010 to 2013,
President and Chief Executive Officer of the North American
division from 2007 to 2010 and President of Medimmune, the
wholly-owned biologics division of AstraZeneca, from 2008 to 2010.
Under Mr. Zook’s leadership, AstraZeneca commercialized ten
blockbuster brands, each over $1 billion in sales. Along with the
CEO, CFO, and Head of R&D, Mr. Zook sat on the Portfolio
Investment Board (PIB), which set and approved the overall strategy
for Research and Development and allocated resources by therapeutic
area.
Mr. Zook served or continues to serve on several boards, including
the boards of AltheRx, Inhibikase, Rib-X Pharmaceuticals, the
National Pharmaceutical Council, PhRMA, the Pennsylvania Division
of the American Cancer Society and his alma mater, Frostburg State
University. Mr. Zook earned a B.S. degree from Frostburg State
University and an A.A. degree in chemical engineering from
Pennsylvania State University.
“The rapid progress made by our subsidiary ViralClear
Pharmaceuticals, Inc. would not have been possible without Tony’s
expert guidance and leadership. We are delighted that Tony accepted
the offer to join the Board of the parent company, a role that will
allow him to assist us in the development of our pharmaceutical
business,” stated Kenneth L. Londoner, Chairman, and CEO of BioSig
Technologies, Inc.
“The ongoing and briskly progressing Phase II clinical trial of
ViralClear could be an important inflection point in the
development of ViralClear. From working to execute the trial and
collect patient data, to preparing for the next steps, we have an
ambitious plan in front of us. I’m pleased to provide my executive
and operating expertise to support the Company’s goals and
objectives,” commented Mr. Zook.
ViralClear recently opened patient
enrollment in six hospitals across the country,
including three Mayo Clinic sites and St. David’s South Austin
Medical Center in Austin, TX. The Company partnered with
Catalent, the leading global provider of advanced delivery
technologies, development, and manufacturing solutions for drugs,
biologics, cell and gene therapies, and consumer health products,
to work on the development of a potential treatment for adults with
advanced Coronavirus Disease 2019 (COVID-19).
About BioSig Technologies
BioSig Technologies is a medical technology company commercializing
a proprietary biomedical signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System, is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About Viral Clear Pharmaceuticals and Merimepodib
(MMPD)
BioSig’s subsidiary, ViralClear Pharmaceuticals, Inc., is seeking
to develop a novel pharmaceutical called merimepodib to treat
patients with COVID-19. Merimepodib is intended to be orally
administered, and has demonstrated broad-spectrum in vitro
antiviral activity, including strong activity against SARS-CoV-2 in
cell cultures. Merimepodib was previously in development as a
treatment for chronic hepatitis C and psoriasis by Vertex
Pharmaceuticals Incorporated (Vertex), with 12 clinical trials (7
in phase 1 and 5 in phase 2) with over 400 subjects and patients
and an extensive preclinical safety, package was completed. A
manuscript titled, “The IMPDH inhibitor merimepodib provided in
combination with the adenosine analog remdesivir reduces SARS-CoV-2
replication to undetectable levels in vitro”, was submitted to an
online peer-reviewed life sciences journal. This manuscript is
authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo,
John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB
Galveston National Laboratory and Dr. Jerome Zeldis , a board
member of BioSig who is helping oversee ViralClear, as a
corresponding author. This article highlights preclinical data
generated under contract with Galveston National Laboratory at The
University of Texas Medical Branch.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation
to publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024